MFSD7C protects hemolysis-induced lung impairments by inhibiting ferroptosis

Area of Science:

• Cell Biology
• Pulmonology
• Biochemistry

Background:

• Hemolysis is linked to lung injury and poor outcomes in diseases like malaria and sickle cell disease (SCD).
• The pathological mechanisms connecting hemolysis to lung damage are not fully understood.
• Ferroptosis, a form of regulated cell death, is implicated in various cellular damages.

Purpose of the Study:

• To investigate the role of Major Facilitator Superfamily Domain Containing 7C (MFSD7C) in protecting the lung from hemolysis-induced injury.
• To elucidate the molecular mechanisms by which MFSD7C influences ferroptosis in the context of hemolytic complications.
• To evaluate the therapeutic potential of MFSD7C in preventing lung injury in hemolytic disease models.

Main Methods:

• Investigated MFSD7C's role in HuLEC-5A cells under hemolytic conditions.
• Analyzed mitochondrial function, lipid remodeling, and ferroptosis markers (ACSL4, GPX4).
• Administered MFSD7C mRNA-loaded nanoparticles in mouse models of hemolysis (HbSS-Townes and PHZ-challenged 7C-/- mice).

Main Results:

• MFSD7C deficiency in cells promoted mitochondrial dysfunction, altered lipid profiles, and increased lipid peroxidation, leading to ferroptosis.
• Systemic delivery of MFSD7C mRNA nanoparticles successfully prevented lung injury in experimental hemolytic mice.
• The study identified a direct link between hemolytic complications and ferroptosis.

Conclusions:

• MFSD7C acts as a protective factor against ferroptosis in hemolytic lung injury.
• MFSD7C deficiency exacerbates lung damage through ferroptosis induction.
• MFSD7C represents a promising therapeutic target for managing lung complications in hemolytic disorders.